SCHEMBL4568205

SCHEMBL4568205

CCOC(=O)c1cccc(Cc2c(-c3cncs3)[nH]c3cc(OC)ccc23)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.40
NPC1 O15118 5/20 0.40
KDM4E B2RXH2 5/20 0.40
RAB9A P51151 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
ALDH1A1 P00352 5/20 0.39
HPGD P15428 3/20 0.39
HSD17B10 Q99714 2/20 0.38
MEN1 O00255 1/20 0.38
ALOX15 P16050 1/20 0.38
KMT2A Q03164 1/20 0.38
GABRA1 P14867 4/20 0.38
GABRG2 P18507 4/20 0.38
GABRB3 P28472 4/20 0.38
GABRA5 P31644 4/20 0.38
GABRA3 P34903 4/20 0.38
GABRA2 P47869 4/20 0.38
LMNA P02545 2/20 0.38
CYP1A2 P05177 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3701562 0.90 GPR17 (0.40) KDM4EALDH1A1HPGDHSD17B10DYRK1A
SCHEMBL4568200 0.83 KDM4E (0.40) MAPTNPC1KDM4ERAB9ASMN1; SMN2
SCHEMBL3698700 0.82 TUBB4A (0.44) MAPTNPC1KDM4ERAB9ASMN1; SMN2
SCHEMBL4568045 0.82 MAPT (0.39) MAPTNPC1KDM4ERAB9ASMN1; SMN2
SCHEMBL4568173 0.81 MAPK13 (0.48) MAPTNPC1KDM4ERAB9ASMN1; SMN2
SCHEMBL4568191 0.81 KDM4E (0.40) MAPTNPC1KDM4ERAB9ASMN1; SMN2
SCHEMBL4568177 0.81 TUBB4A (0.43) MAPTNPC1KDM4ERAB9ASMN1; SMN2
SCHEMBL4568199 0.81 ALDH1A1 (0.45) MAPTNPC1KDM4ERAB9ASMN1; SMN2
SCHEMBL4568180 0.80 MEN1 (0.41) MAPTNPC1KDM4ERAB9ASMN1; SMN2
SCHEMBL4568194 0.80 PTGS2 (0.38) MAPTNPC1KDM4ERAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2474530-B1 INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL (JP) 2014-09-03 EP disclosed
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF PTGER1, CYSLTR1, LTB4R MAPT 3199/4885NPC1 1150/4885KDM4E 3521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.